NCT02073838View on ClinicalTrials.gov

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Ribavirin

DRUG

Vismodegib

DRUG

Decitabine

Trial Locations (1)

H3T1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Sarit Assouline

OTHER

NCT02073838 - Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | Biotech Hunter | Biotech Hunter